The incidence of acute myeloid leukemia (AML) has increased due to an aging population, risk from environmental exposures, and treatment-related/secondary AML in survivors of young and childhood cancers. Members of the hematology/oncology care team are challenged to keep apprised of clinical data, incorporate novel agents into their clinical practice, and manage side effects of newer therapies. In this activity, Dr Daniel Pollyea and Dr Amer Zeidan provide expert commentary on 2 challenging clinical case scenarios focused on management of AML.

Click on this link to access the program:

https://www.rapidcme.com/activity.aspx?actid=84